Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

KRAS mutation: from undruggable to druggable in cancer

Open access
Huang, Lamei, Guo, Zhixing, Wang, Fang, Fu, Liwu · 2021 · Signal Transduction and Targeted Therapy

Abstract

Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of KRAS is constantly being updated by numerous studies on KRAS in the initiation and progression of cancer diseases. However, KRAS has been deemed a challenging therapeutic target, even “undruggable”, after drug-targeting efforts over the past four decades. Recently, there have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved for clinical use this year. This review summarises the most recent understanding of fundamental aspects of KRAS, the relationship between the KRAS mutations and tumour immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C). Moreover, the possible mechanisms of resistance to KRAS (G12C) inhibitors and possible combination therapies are summarised, with a view to providing the best regimen for individualised treatment with KRAS (G12C) inhibitors and achieving truly precise treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00780-4

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The structure and function of KRAS. a According to homology, KRAS, which consists of 188/189 amino acids can be divided into three parts. The first part consisting of the first 85 amino acid residues is a highly conserved region. The next 80 amino acid residues are defined as a second part where homology between any pair of human RAS genes is 85%. A third part is a highly variable region and homology is only 8%. KRAS forms two major domains: a catalytic domain called the G domain and a hypervariable region (HVR). The G domain consists of three regions: switch I, switch II and the P loop, which binds guanine nucleotides and activates signalling pathway by interacting with effectors. The HVR consists of a membrane-targeting domain containing the CAAX motif where C is a cysteine, A is any aliphatic amino acid and X is any amide acid, which acquires lipids by farnesyl or prenyl modification. b The normal function of KRAS depends on the membrane localisation of its post-transcriptional modification, which is mediated by a series of enzymes. KRAS functions as a guanosine diphosphate (GDP)/triphosphate (GTP) binary switch, which controls important signal transduction from activated membrane receptors to intracellular molecules. The binary switch is mainly determined by two kinds of regulatory proteins: guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). FTase: farnesyltransferase; GGTase: geranyl geranyltransferase; RCE1: RAS-converting enzyme 1; ICMT: isoprenylcysteine carboxyl methyltransferase; PDEδ: phosphodiesterase δ
Fig. 1 The structure and function of KRAS. a According to homology, KRAS, which consists of 188/189 amino acids can be divided into three parts. The first part consisting of the first 85 amino acid residues is a highly conserved region. The next 80 amino acid residues are defined as a second part where homology between any pair of human RAS genes is 85%. A third part is a highly variable region and homology is only 8%. KRAS forms two major domains: a catalytic domain called the G domain and a hypervariable region (HVR). The G domain consists of three regions: switch I, switch II and the P loop, which binds guanine nucleotides and activates signalling pathway by interacting with effectors. The HVR consists of a membrane-targeting domain containing the CAAX motif where C is a cysteine, A is any aliphatic amino acid and X is any amide acid, which acquires lipids by farnesyl or prenyl modification. b The normal function of KRAS depends on the membrane localisation of its post-transcriptional modification, which is mediated by a series of enzymes. KRAS functions as a guanosine diphosphate (GDP)/triphosphate (GTP) binary switch, which controls important signal transduction from activated membrane receptors to intracellular molecules. The binary switch is mainly determined by two kinds of regulatory proteins: guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). FTase: farnesyltransferase; GGTase: geranyl geranyltransferase; RCE1: RAS-converting enzyme 1; ICMT: isoprenylcysteine carboxyl methyltransferase; PDEδ: phosphodiesterase δCC BY · PubMed Central
Fig. 2 The regulation of KRAS activation and signal transduction. The canonical and well-known pattern of activating KRAS is dependent on correct membrane localisation and adjacent activation of membrane receptors. In the resting state, KRAS normally binds with GDP in an inactivated state. When the extracellular growth factors such as EGF transmit signals to receptors, the SOS, a kind of GEF, interacts with the KRAS-GDP complex leading to the release of GDP and the replacement of GTP. The tether of GTP and KRAS induces structural changes of switch I and switch II, thereby activating KRAS. In contrast, GAPs enhance intrinsic GTPase activity in KRAS to accelerate the reaction in which GTP is hydrolysed to GDP. The KRAS cycle between the activated and inactivated conformations functions as a finely regulated molecular switch that controls multiple signalling cascades, including the canonical RAF-MEK-ERK pathway, which controls proliferation; PI3K-AKT-mTOR pathway, which promotes cell survival; and other signalling pathways, which are required for KRAS-dependent tumour growth and endocytosis, and cytoskeletal organisation
Fig. 2 The regulation of KRAS activation and signal transduction. The canonical and well-known pattern of activating KRAS is dependent on correct membrane localisation and adjacent activation of membrane receptors. In the resting state, KRAS normally binds with GDP in an inactivated state. When the extracellular growth factors such as EGF transmit signals to receptors, the SOS, a kind of GEF, interacts with the KRAS-GDP complex leading to the release of GDP and the replacement of GTP. The tether of GTP and KRAS induces structural changes of switch I and switch II, thereby activating KRAS. In contrast, GAPs enhance intrinsic GTPase activity in KRAS to accelerate the reaction in which GTP is hydrolysed to GDP. The KRAS cycle between the activated and inactivated conformations functions as a finely regulated molecular switch that controls multiple signalling cascades, including the canonical RAF-MEK-ERK pathway, which controls proliferation; PI3K-AKT-mTOR pathway, which promotes cell survival; and other signalling pathways, which are required for KRAS-dependent tumour growth and endocytosis, and cytoskeletal organisationCC BY · PubMed Central
Fig. 3 KRAS mutation in cancer. a The frequency of KRAS mutations across tumour types, including the mutation frequency of common sites and the subtype with the highest mutation rate in different tumour types. KRAS mutations are characterised by single-base missense mutations, 98% of which are found at codon 12, codon 13, or codon 61. Please refer to Table 1 for specific figures. b Specific mutant subtypes and percentages were represented in the top three cancers with the highest mutation rates of KRAS including pancreatic cancer, colorectal cancer, and nonsmall-cell lung cancer. c Frequency of co-occurring aberrations in KRAS mutant cells. Only a mutant prevalence of at least 3% is shown in addition to EGFR mutation, given the important effect of EGFR mutation on NSCLC. TP53: tumour protein p53 gene; DDR2: discoidin domain receptor tyrosine kinase 2 gene; MET: MNNG HOST Transforming gene; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; STK11: serine/threonine kinase 11 gene; KEAP1: kelch-like ECH-associated protein 1 gene; ATM: ATM serine/threonine kinase gene, PIK3CG: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma gene; ERBB4: erb-b2 receptor tyrosine kinase 4 gene; KDR: kinase insert domain receptor gene; KIT: KIT proto-oncogene receptor tyrosine kinase gene; NFE2L2 nuclear factor erythroid 2, like 2 gene; PDGFR previous symbol of PDGFRB (platelet-derived growth factor receptor beta gene). Data acquired from The Cancer Genome Atlas (pan-Cancer) from cBioPortal
Fig. 3 KRAS mutation in cancer. a The frequency of KRAS mutations across tumour types, including the mutation frequency of common sites and the subtype with the highest mutation rate in different tumour types. KRAS mutations are characterised by single-base missense mutations, 98% of which are found at codon 12, codon 13, or codon 61. Please refer to Table 1 for specific figures. b Specific mutant subtypes and percentages were represented in the top three cancers with the highest mutation rates of KRAS including pancreatic cancer, colorectal cancer, and nonsmall-cell lung cancer. c Frequency of co-occurring aberrations in KRAS mutant cells. Only a mutant prevalence of at least 3% is shown in addition to EGFR mutation, given the important effect of EGFR mutation on NSCLC. TP53: tumour protein p53 gene; DDR2: discoidin domain receptor tyrosine kinase 2 gene; MET: MNNG HOST Transforming gene; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; STK11: serine/threonine kinase 11 gene; KEAP1: kelch-like ECH-associated protein 1 gene; ATM: ATM serine/threonine kinase gene, PIK3CG: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma gene; ERBB4: erb-b2 receptor tyrosine kinase 4 gene; KDR: kinase insert domain receptor gene; KIT: KIT proto-oncogene receptor tyrosine kinase gene; NFE2L2 nuclear factor erythroid 2, like 2 gene; PDGFR previous symbol of PDGFRB (platelet-derived growth factor receptor beta gene). Data acquired from The Cancer Genome Atlas (pan-Cancer) from cBioPortalCC BY · PubMed Central
Fig. 4 KRAS-mediated immune escape in tumour microenvironment. KRAS mediates immune escape in the tumour macroenvironment by upregulating PD-L1expression, downregulating MHC1expression of tumour cells, and enhancing the secretion of a variety of cytokines and chemokines to recruit immunosuppressive immune cells. The black arrow represents facilitation, and the opposite red arrow represents inhibition. MDSCs: myeloid-derived suppressor cells; Treg cells: regulatory T cells; IL-10: interleukin-10; TGF-β: transforming growth factor-β; GM-CSF: granulocyte-macrophage colony-stimulating factor; IL-23: interleukin-23
Fig. 4 KRAS-mediated immune escape in tumour microenvironment. KRAS mediates immune escape in the tumour macroenvironment by upregulating PD-L1expression, downregulating MHC1expression of tumour cells, and enhancing the secretion of a variety of cytokines and chemokines to recruit immunosuppressive immune cells. The black arrow represents facilitation, and the opposite red arrow represents inhibition. MDSCs: myeloid-derived suppressor cells; Treg cells: regulatory T cells; IL-10: interleukin-10; TGF-β: transforming growth factor-β; GM-CSF: granulocyte-macrophage colony-stimulating factor; IL-23: interleukin-23CC BY · PubMed Central
Fig. 5 Current targeted strategies for KRAS (G12C). a Despite the mutation occurring in KRAS, KRAS (G12C) still continues to perform the KRAS-GDP/GTP cycle. Covalent inhibitors such as AMG510 and MRTX849 lock KRAS (G12C) in inactivated GDP-bound state, thus decreasing functional KRAS. Another strategy is to increase the degradation of mutant KRAS (G12C) proteins. Based on the previously described KRAS (G12C) covalent inhibitors, LC-2, an endogenous KRAS (G12C) degrader, has been developed to promote KRAS (G12C) degradation. b The development and chemical structures of KRAS (G12C) inhibitors
Fig. 5 Current targeted strategies for KRAS (G12C). a Despite the mutation occurring in KRAS, KRAS (G12C) still continues to perform the KRAS-GDP/GTP cycle. Covalent inhibitors such as AMG510 and MRTX849 lock KRAS (G12C) in inactivated GDP-bound state, thus decreasing functional KRAS. Another strategy is to increase the degradation of mutant KRAS (G12C) proteins. Based on the previously described KRAS (G12C) covalent inhibitors, LC-2, an endogenous KRAS (G12C) degrader, has been developed to promote KRAS (G12C) degradation. b The development and chemical structures of KRAS (G12C) inhibitorsCC BY · PubMed Central
Fig. 6 Combinational strategies for KRAS (G12C) inhibitors. The combined strategy of KRAS (G12C) inhibitors is mainly divided into four parts: combined with chemoradiotherapy, targeted therapy, immune therapy, and metabolic therapy
Fig. 6 Combinational strategies for KRAS (G12C) inhibitors. The combined strategy of KRAS (G12C) inhibitors is mainly divided into four parts: combined with chemoradiotherapy, targeted therapy, immune therapy, and metabolic therapyCC BY · PubMed Central
Fig. 7 Acquired resistance mechanism of covalent KRAS (G12C) inhibitors. The figure on the left blue background represents cells that are sensitive to KRAS (G12C) inhibitors, while the figure on right red background represents cells that are resistant to inhibitors. The black dotted line represents inhibition of KRAS signalling in the presence of KRAS (G12C) inhibitors. The solid red lines represent the resistance mechanisms identified after the use of KRAS (G12C) inhibitors, including the relief of ERK-mediated feedback inhibition, which reactivates the MAPK pathway by wild-type RAS (NRAS and HRAS) or new synthetic KRAS (G12C); the activation of other bypasses, such as PI3K activation by the IGFR–IRS1 pathway and secondary or additional mutations in KRAS. This figure generated from BioRender
Fig. 7 Acquired resistance mechanism of covalent KRAS (G12C) inhibitors. The figure on the left blue background represents cells that are sensitive to KRAS (G12C) inhibitors, while the figure on right red background represents cells that are resistant to inhibitors. The black dotted line represents inhibition of KRAS signalling in the presence of KRAS (G12C) inhibitors. The solid red lines represent the resistance mechanisms identified after the use of KRAS (G12C) inhibitors, including the relief of ERK-mediated feedback inhibition, which reactivates the MAPK pathway by wild-type RAS (NRAS and HRAS) or new synthetic KRAS (G12C); the activation of other bypasses, such as PI3K activation by the IGFR–IRS1 pathway and secondary or additional mutations in KRAS. This figure generated from BioRenderCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 240 references

Research works printed but not linked: 6

  1. Hunter, J. C. et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol. Cancer Res. 13, 1325–1335 (2015). · DOI · Paper page
  2. Hunter, J. C. et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol. Cancer Res 13, 1325–1335 (2015). · DOI · Paper page
  3. Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med 23, 1362–1368 (2017). · DOI · Paper page
  4. Hallin, J. et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Disco. 10, 54–71 (2020). · DOI · Paper page
  5. Hallin, J. et al. The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 10, 54–71 (2020). · DOI · Paper page
  6. Tanaka, N. et al. Clinical Acquired Resistance to KRAS Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 11, 1913–1922 (2021). · DOI · Paper page

Cited by

See all 1,127

Metadata

Authors
Huang, L., Guo, Z., Wang, F., & Fu, L.
Affiliations
Sun Yat-sen University (CN)
Corresponding author
Fu, Liwu
Venue
Signal Transduction and Targeted Therapy
Published
2021-11-15
Volume
6
Issue
1
Pages
386-386
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3214173072
Cited by
1,127
References
240
Citations by year
2026: 251 · 2025: 346 · 2024: 289 · 2023: 178 · 2022: 62
FWCI
14.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82073882)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS mutation, KRAS G12C inhibitors, sotorasib, adagrasib, targeted cancer therapy, tumor immune evasion, drug resistance mechanisms, combination therapy, oncogenes, precision oncology
MeSH terms
Humans, Neoplasms, Proto-Oncogene Proteins p21(ras), Amino Acid Substitution, Mutation, Missense, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS mutation: from undruggable to druggable in cancer. https://app.cochat.ai/papers/10.1038/s41392-021-00780-4
The paper
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00780-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.